Imaging Hepatocellular Carcinoma With 68 Ga-Citrate PET: First Clinical Experience
Molecular Imaging · 01.01.2017 · 16
DOI: 10.1177/1536012117723256 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Imaging, online erschienen am 11.09.2017. Verfasst von Carina Mari Aparici und 7 weiteren Autor:innen. Beteiligte Einrichtung: 1 Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA. Hauptthemen laut MEDLINE: Positron-Emission Tomography. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NCI NIH HHS, Prostate Cancer Foundation.
Abstract (Originalsprache)
While cross-sectional imaging with computed tomography (CT) and magnetic resonance imaging is the primary method for diagnosing hepatocellular carcinoma (HCC), they provide little biological insight into this molecularly heterogeneous disease. Nuclear imaging tools that can detect molecular subsets of tumors could greatly improve diagnosis and management of HCC. To this end, we conducted a patient study to determine whether HCC can be resolved using 68 Ga-citrate positron emission tomography (PET). One patient with recurrent HCC was injected with 300 MBq of 68 Ga-citrate and imaged with PET/CT 249 minutes post injection. Four (28%) of 14 hepatic lesions were avid for 68 Ga-citrate. One extrahepatic lesion was not PET avid. The average maximum standardized uptake value (SUV max ) for the lesions was 7.2 (range: 6.2-8.4), while the SUV max of the normal liver parenchyma was 4.7 and blood pool was 5.7. The avid lesions were not significantly larger than the quiescent lesions, and a prior contrast CT showed uniform enhancement among the lesions, suggesting that tumor signals are due to specific binding of the radiotracer to the transferrin receptor, rather than enhanced vascularity in the tumor microenvironment. Further studies are required in a larger patient cohort to verify the molecular basis of radiotracer uptake and the clinical utility of this tool.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 1 Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA.
- 2 Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.
- 3 Department of Surgery, University of California, San Francisco, San Francisco, CA, USA.
- 4 Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.
Förderung
- NIDDK NIH HHS
- NCI NIH HHS
- Prostate Cancer Foundation
- U.S. Department of Defense
- National Cancer Institute
Zitieren
APA
Mari Aparici, C., Behr, S. C., Seo, Y., Kelley, R. K., Corvera, C., Gao, K. T., Aggarwal, R., & Evans, M. J. (2017). Imaging Hepatocellular Carcinoma With 68 Ga-Citrate PET: First Clinical Experience. Molecular Imaging, 16. https://doi.org/10.1177/1536012117723256
Vancouver
Mari Aparici C, Behr SC, Seo Y, Kelley RK, Corvera C, Gao KT, et al. Imaging Hepatocellular Carcinoma With 68 Ga-Citrate PET: First Clinical Experience. Molecular Imaging. 2017;16. doi:10.1177/1536012117723256
BibTeX
@article{MariAparici2017,
author = {Mari Aparici, Carina and Behr, Spencer C and Seo, Youngho and Kelley, R Kate and Corvera, Carlos and Gao, Kenneth T and Aggarwal, Rahul and Evans, Michael J},
title = {Imaging Hepatocellular Carcinoma With 68 Ga-Citrate PET: First Clinical Experience},
journal = {Molecular Imaging},
year = {2017},
volume = {16},
doi = {10.1177/1536012117723256}
}
EUVIMED